Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium
Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Oragenics (NYSE American: OGEN), a biotech company focused on intranasal therapeutics for brain-related conditions, announces its participation in two major industry events in June 2025. Greg Gironda, Head of Business Development, will present at the 2025 BIO International Convention in Boston (June 16-19), where he will discuss ONP-002, the company's lead intranasal neurosteroid candidate for treating concussion. Additionally, Oragenics will attend the 42nd Annual National Neurotrauma Society Symposium in Philadelphia (June 15-18), co-hosted by the National Neurotrauma Society and AANS/CNS Joint Section on Neurotrauma & Critical Care. These events provide platforms for Oragenics to showcase its development pipeline and engage with industry leaders in neuroscience, neurology, biotech, and pharma.
Oragenics (NYSE American: OGEN), un'azienda biotecnologica specializzata in terapie intranasali per condizioni cerebrali, annuncia la sua partecipazione a due importanti eventi del settore a giugno 2025. Greg Gironda, Responsabile dello Sviluppo Commerciale, presenter脿 al BIO International Convention 2025 a Boston (16-19 giugno), dove parler脿 di ONP-002, il principale candidato neurosteroide intranasale dell'azienda per il trattamento della commozione cerebrale. Inoltre, Oragenics parteciper脿 al 42掳 Simposio Annuale della National Neurotrauma Society a Filadelfia (15-18 giugno), co-organizzato dalla National Neurotrauma Society e dalla Sezione Congiunta AANS/CNS su Neurotrauma e Cure Critiche. Questi eventi offrono a Oragenics l'opportunit脿 di mostrare il proprio pipeline di sviluppo e di confrontarsi con leader del settore nelle neuroscienze, neurologia, biotecnologia e farmaceutica.
Oragenics (NYSE American: OGEN), una empresa biotecnol贸gica centrada en terapias intranasales para condiciones cerebrales, anuncia su participaci贸n en dos importantes eventos de la industria en junio de 2025. Greg Gironda, Jefe de Desarrollo Comercial, presentar谩 en la Convenci贸n Internacional BIO 2025 en Boston (16-19 de junio), donde hablar谩 sobre ONP-002, el principal candidato neuroesteroide intranasal de la compa帽铆a para el tratamiento de conmociones cerebrales. Adem谩s, Oragenics asistir谩 al 42潞 Simposio Anual de la National Neurotrauma Society en Filadelfia (15-18 de junio), coorganizado por la National Neurotrauma Society y la Secci贸n Conjunta AANS/CNS sobre Neurotrauma y Cuidados Cr铆ticos. Estos eventos ofrecen a Oragenics plataformas para mostrar su pipeline de desarrollo y relacionarse con l铆deres de la industria en neurociencia, neurolog铆a, biotecnolog铆a y farmac茅utica.
Oragenics(NYSE American: OGEN)電� 雵� 甏�霠� 歆堩櫂鞐� 雽�頃� 牍勱皶 雮� 旃橂鞝滌棎 欤茧牓頃橂姅 氚旍澊鞓ろ厡韥� 旮办梾鞙茧, 2025雲� 6鞗� 霊� 臧滌潣 欤检殧 靷办梾 頄夓偓鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 靷梾臧滊皽 毂呾瀯鞛愳澑 Greg Gironda電� 2025雲� 6鞗� 16鞚茧秬韯� 19鞚缄箤歆� 氤挫姢韯挫棎靹� 鞐措Μ電� BIO 甑牅 旎菠靺橃棎靹� 須岇偓鞚� 欤检殧 牍勱皶 雮� 鞁犼步鞀ろ厡搿滌澊霌� 頉勲炒氍检鞚� ONP-002毳� 靻岅皽頃橂┌ 雵岇韮� 旃橂鞐� 雽�頃� 氚滍憸頃� 鞓堨爼鞛呺媹雼�. 霕愴暅 Oragenics電� 6鞗� 15鞚茧秬韯� 18鞚缄箤歆� 頃勲澕雿疙敿鞎勳棎靹� 臧滌禍霅橂姅 鞝�42須� 鞐半 National Neurotrauma Society 鞁彫歆�鞐勳棎霃� 彀胳劃頃橂┌, 鞚� 頄夓偓電� National Neurotrauma Society鞕� AANS/CNS 瓿惦彊 鞁犼步鞕胳儊 氚� 欷戫櫂鞛� 甏�毽� 攵勱臣臧� 瓿惦彊 欤检禍頃╇媹雼�. 鞚� 頄夓偓霌れ潃 Oragenics臧� 臧滊皽 韺岇澊頂勲澕鞚胳潉 靹犽炒鞚搓碃 鞁犼步瓿柬暀, 鞁犼步頃�, 氚旍澊鞓ろ厡韥�, 鞝滌暯 攵勳暭鞚� 鞐呹硠 毽崝霌り臣 甑愲頃� 靾� 鞛堧姅 旮绊殞毳� 鞝滉车頃╇媹雼�.
Oragenics (NYSE American : OGEN), une entreprise biotechnologique sp茅cialis茅e dans les th茅rapies intranasales pour les affections c茅r茅brales, annonce sa participation 脿 deux 茅v茅nements majeurs de l'industrie en juin 2025. Greg Gironda, responsable du d茅veloppement commercial, pr茅sentera lors de la Convention Internationale BIO 2025 脿 Boston (du 16 au 19 juin), o霉 il abordera ONP-002, le principal candidat neurost茅ro茂de intranasal de la soci茅t茅 pour le traitement des commotions c茅r茅brales. Par ailleurs, Oragenics assistera au 42e Symposium annuel de la National Neurotrauma Society 脿 Philadelphie (du 15 au 18 juin), co-organis茅 par la National Neurotrauma Society et la section conjointe AANS/CNS sur le neurotraumatisme et les soins intensifs. Ces 茅v茅nements offrent 脿 Oragenics des plateformes pour pr茅senter son pipeline de d茅veloppement et 茅changer avec les leaders de l'industrie en neurosciences, neurologie, biotechnologie et pharmacie.
Oragenics (NYSE American: OGEN), ein Biotechnologieunternehmen, das sich auf intranasale Therapien f眉r gehirnbezogene Erkrankungen spezialisiert hat, k眉ndigt seine Teilnahme an zwei wichtigen Branchenevents im Juni 2025 an. Greg Gironda, Leiter Gesch盲ftsentwicklung, wird auf der BIO International Convention 2025 in Boston (16.-19. Juni) pr盲sentieren und dabei ONP-002 vorstellen, den f眉hrenden intranasalen Neurosteroid-Kandidaten des Unternehmens zur Behandlung von Gehirnersch眉tterungen. Zudem wird Oragenics am 42. Jahressymposium der National Neurotrauma Society in Philadelphia (15.-18. Juni) teilnehmen, das gemeinsam von der National Neurotrauma Society und der AANS/CNS Joint Section on Neurotrauma & Critical Care veranstaltet wird. Diese Veranstaltungen bieten Oragenics die M枚glichkeit, seine Entwicklungspipeline zu pr盲sentieren und sich mit Branchenf眉hrern aus den Bereichen Neurowissenschaften, Neurologie, Biotechnologie und Pharma auszutauschen.
Positive
- None.
Negative
- None.
SARASOTA, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced that Greg Gironda, Head of Business Development, will present at the 2025 BIO International Convention, taking place June 16鈥�19, 2025, in Boston, Massachusetts. In addition, Oragenics will also attend the 42nd Annual National Neurotrauma Society (NNS) Symposium, being held June 15鈥�18, 2025, in Philadelphia, Pennsylvania.
These back-to-back events represent key opportunities for Oragenics to highlight its lead candidate, ONP-002, an intranasal neurosteroid in development for the treatment of concussion (mild traumatic brain injury), and to engage with global leaders in neuroscience, neurology, biotech, and pharma.
2025 BIO International Convention
- Dates: June 16鈥�19, 2025
- Location: Boston Convention & Exhibition Center, Boston, MA
- Presentation Date & Time: June 19, 2025, from 11:30 AM 鈥� 11:45 AM ET
- Registration:
42nd Annual National Neurotrauma Society (NNS) Symposium
- Dates: June 15鈥�18, 2025
- Location: Philadelphia Marriott Downtown, Philadelphia, PA
- Co-hosts: National Neurotrauma Society and AANS/CNS Joint Section on Neurotrauma & Critical Care
About Oragenics, Inc.
Oragenics is a biotechnology company focused on developing intranasal therapeutics for neurological disorders. Its lead candidate, ONP-002, is being developed for the treatment of mild traumatic brain injury (mTBI), commonly known as concussion. The Company鈥檚 intranasal delivery technology is designed to deliver fast, targeted, and non-invasive therapy to the brain. For more information, please visit .
Investor Contact:
Rich Cockrell
CG Capital
866.889.1972
[email protected]
FAQ
When and where will Oragenics (OGEN) present at the 2025 BIO International Convention?
Oragenics will present on June 19, 2025, from 11:30 AM to 11:45 AM ET at the Boston Convention & Exhibition Center in Boston, MA.
What is Oragenics' (OGEN) lead drug candidate ONP-002?
ONP-002 is an intranasal neurosteroid being developed for the treatment of concussion (mild traumatic brain injury).
Which two major industry events will Oragenics (OGEN) attend in June 2025?
Oragenics will attend the 2025 BIO International Convention in Boston (June 16-19) and the 42nd Annual National Neurotrauma Society Symposium in Philadelphia (June 15-18).
Who will represent Oragenics (OGEN) at the 2025 BIO International Convention?
Greg Gironda, Head of Business Development at Oragenics, will present at the convention.
Oragenics
NYSE:OGEN
OGEN Latest News
OGEN Latest SEC Filings
Jul 1, 2025
[EFFECT] Oragenics Inc. SEC Filing
Jun 18, 2025
[Form 4] Oragenics Inc. Insider Trading Activity
OGEN Stock Data
2.55M
698.42k
13.3%
1.14%
2.86%
Biotechnology
Pharmaceutical Preparations
United States
SARASOTA